All News
Testosterone Therapy Yields No Cardiovascular Harm
Are the benefits of androgen supplementation in older men overstated? Might the risks be understated?
Read ArticleStatins Improve CV risk in RA
Since publication of the Jupiter trial that showed statin effects may include the lowering of C-reactive protein levels and inflammation, there have been several efforts to study the adjunctive effects of statins in rheumatoid arthritis treatment.
Read ArticleCV Risk in RA: Is a New Measurement Tool the Answer?
A new expanded cardiovascular (CV) risk calculator for use in patients with rheumatoid arthritis (RA) has been developed to take into account disease-specific factors that can worsen risk, researchers reported.
Read ArticleLipid Levels and CV Events in RA
Rheumatoid arthritis not only affects the joints but can also increase risk for cardiovascular disease. The mechanism of the increased risk of cardiovascular disease in rheumatoid arthritis remains uncertain.
Read Article2015 Guidelines for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing form of interstitial pneumonia, with poor survival rates of nearly 50% at 3 years.
Read ArticleFDA Strengthens MI and CVA Risks Associated with NSAIDs
FDA announced yesterday they would strengthen warnings stating that non-aspirin nonsteroidal anti-inflammatory drugs increase the chance of a heart attack or stroke. This applies to both prescription and OTC NSAIDs.
Read ArticleDoes ACPA Increase the Risk of Interstitial Lung Disease?
The anti-citrullinated peptide (anti-CCP or ACPA) antibody assay has a specificity of greater than 90% for rheumatoid arthritis and is associated with worse articular outcomes.
Read ArticleTroponin and BNP in the Diagnosis of Pulmonary Hypertension
Common cardiac biomarkers could be used to identify patients with systemic sclerosis (SSc) at risk for developing pulmonary hypertension, French researchers reported.
Read ArticleMicroscopic Polyangiitis Associated with Pulmonary Fibrosis
Brain Natriuretic Peptide Measurement in Rheumatoid Arthritis
Cardiovascular (CV) risk and adverse cardiac outcomes are common in rheumatoid arthritis (RA). It has been presumed that chronic systemic inflammation has a deleterious effect on the myocardium and vasculature, thereby leading to higher rates of MI, CHF and CV death.
Read ArticleTargeting Autoantibodies in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis carries a high mortality rate and can be a management challenge. Moreover, exacerbations of IPF may be fatal. A multicenter uncontrolled study examined the utility of targeting autoantibody production with revealed surprising results.
Read ArticleThe EULAR 2015 Report- Friday
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
Read ArticleAllopurinol Reduces Mortality in Gout
CVD risk is significantly augmented in gout. Choi and coworkers studied this issue using a UK general population database using an incident user cohort study with propensity score matching.
Read ArticleDifficulties Diagnosing Interstitial Lung Disease in Scleroderma
The diagnosis of chronic lung disease in patients with systemic sclerosis may be difficult because of atypical symptoms, variable evolution and limitations of current classification criteria for a definite diagnosis. Nevertheless, diagnosis is necessary as patients with SSc-ILD have a p
Read ArticleEarly DMARD Therapy Averts Cardiovascular Risk in RA
A Finnish early RA register studied 14,878 incident RA patients from 2000-2008 and identified 1157 deaths. Patients receiving DMARDs and MTX had lower mortality rates. The standardized moratility ratio for the entire cohort was reduced (0.57, 95% CI 0.52 to 0.62).
Read Article